Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Robson

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Inorganic Chemistry|July 21, 2017
Mixed Valency in a 3D Semiconducting Iron-Fluoranilate Coordination PolymerRyuichi Murase, Brendan F Abrahams, Deanna M D'Alessandro, et al.
Kidney International Reports|June 2, 2018
Benefit of Apabetalone on Plasma Proteins in Renal DiseaseSylwia Wasiak, Laura M Tsujikawa, Christopher Halliday, et al.
Kidney International|December 24, 2025
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathySean J Barbour, Michelle A Hladunewich, Michael L McCaleb, et al.
Journal of Clinical Pharmacology|February 24, 2006
Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patientsArthur J Bergman, Joanne Burke, Patrick Larson, et al.
Mayo Clinic Proceedings|October 22, 2019
Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 StudiesR Scott Wright, Michael G Collins, Robert M Stoekenbroek, et al.
Inorganic Chemistry|March 4, 2020
Effects of Mixed Valency in an Fe-Based Framework: Coexistence of Slow Magnetic Relaxation, Semiconductivity, and Redox ActivityRyuichi Murase, Christopher J Commons, Timothy A Hudson, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2009
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokineticsMarian Iwamoto, William D Hanley, Amelia S Petry, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|February 8, 2019
Square Grid Metal-Chloranilate Networks as Robust Host Systems for Guest SorptionChristopher J Kingsbury, Brendan F Abrahams, Josie E Auckett, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyEric Lawitz, Charles S Landis, Steven L Flamm, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Inorganic Chemistry|July 21, 2017
Mixed Valency in a 3D Semiconducting Iron-Fluoranilate Coordination PolymerRyuichi Murase, Brendan F Abrahams, Deanna M D'Alessandro, et al.
Kidney International Reports|June 2, 2018
Benefit of Apabetalone on Plasma Proteins in Renal DiseaseSylwia Wasiak, Laura M Tsujikawa, Christopher Halliday, et al.
Kidney International|December 24, 2025
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathySean J Barbour, Michelle A Hladunewich, Michael L McCaleb, et al.
Journal of Clinical Pharmacology|February 24, 2006
Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patientsArthur J Bergman, Joanne Burke, Patrick Larson, et al.
Mayo Clinic Proceedings|October 22, 2019
Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 StudiesR Scott Wright, Michael G Collins, Robert M Stoekenbroek, et al.
Inorganic Chemistry|March 4, 2020
Effects of Mixed Valency in an Fe-Based Framework: Coexistence of Slow Magnetic Relaxation, Semiconductivity, and Redox ActivityRyuichi Murase, Christopher J Commons, Timothy A Hudson, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2009
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokineticsMarian Iwamoto, William D Hanley, Amelia S Petry, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|February 8, 2019
Square Grid Metal-Chloranilate Networks as Robust Host Systems for Guest SorptionChristopher J Kingsbury, Brendan F Abrahams, Josie E Auckett, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyEric Lawitz, Charles S Landis, Steven L Flamm, et al.
Pageof 7